Dr. Patrick's excellent description does not include the Vitamin D Receptor benefits
- Resveratrol improves health (Vitamin D receptor, etc.)
- Resveratrol category listing has
35 items along with related searches
Table of contents
- Resveratrol's effects on human health and disease
- Neurological health and Alzheimer’s disease
- Physiological responses and molecular mechanisms associated with resveratrol intake
Resveratrol is a natural compound found primarily in the skin of red grapes and the root of Polygonum cuspidatum (also known as Japanese knotweed). It is also present to a lesser degree in peanuts and blueberries. Resveratrol protects the plants in which it is present from fungal attack and the damaging effects of ultraviolet radiation.
Originally extracted in the 1940s, resveratrol attracted little interest in terms of human health until 1992 when research suggested that it could mediate some of the cardioprotective effects of red wine. Since then, numerous studies have demonstrated resveratrol's ability to slow or prevent various illnesses, including cancer and cardiovascular disease, as well as extend the lifespan of organisms ranging from yeast to vertebrates. These protective effects are likely due to resveratrol's anti-inflammatory and antioxidant properties and its capacity to activate sirtuin 1, or SIRT1, a type of enzyme that plays a role in aging and longevity.
Resveratrol elicits beneficial health effects when used as a treatment for metabolic diseases such as obesity, glucose intolerance, insulin resistance, hypertension, and fatty liver disease.
In a small clinical trial involving 11 obese people, 150 milligrams of resveratrol treatment for 30 days promoted calorie restriction-like effects. The study participants' systolic blood pressure decreased by ~5mm Hg and they experienced improved circulating glucose, insulin, and triglyceride concentrations compared to when they took a placebo. Multiple studies in people who have type 2 diabetes demonstrate that resveratrol treatment of ~1 gram per day significantly decreases systolic blood pressure, fasting blood glucose, hemoglobin A1c (a measure of long-term blood glucose control), and circulating insulin, while improving insulin sensitivity and increasing high-density lipoprotein levels, when compared to baseline levels and placebo groups.   
Resveratrol activates SIRT1 and AMPK while suppressing mTOR, which may lead to improved healthspan via mechanisms that overlap with caloric restriction.
Patients characterized as having non-alcoholic fatty liver disease who took a resveratrol supplement of either 300 or 500 milligrams per day for three months exhibited decreased serum LDL levels, decreased hepatic steatosis, decreased inflammation markers such as NF-κB, and improved insulin sensitivity. 
In a study involving 75 patients undergoing statin treatment for primary cardiovascular disease prevention, those who took a 350 milligram resveratrol-enriched grape extract daily for six months saw a decrease in multiple cardiovascular risk markers, compared to their baseline measurements. The participants' low-density lipoprotein cholesterol (LDLc) decreased by 4.5 percent, oxidized LDL decreased by 20 percent, and apolipoprotein B decreased by 9.8 percent. After the six-month treatment period, the patients received double the original dose for another six months, which resulted in a decrease of inflammatory markers such as tumor necrosis factor-α and interleukin-6 while increasing the anti-inflammatory marker interleukin-10. Furthermore, in patients who had experienced a heart attack, 10 milligrams of daily resveratrol for three months resulted in a significant decrease in LDLc and improved both left ventricle diastolic function and endothelial function – overall measures of heart health.
Resveratrol treatment also elicits positive outcomes in healthy people by decreasing oxidative and inflammatory stress. Specifically, a six-week course of an extract of Polygonum cuspidatum containing 40 milligrams of resveratrol decreased reactive oxygen species and suppressed the expression of JNK-1 and IKKβ, both of which are mediators of inflammation that reduce pro-inflammatory markers TNF-α and IL-6.
Studies in animals show similar beneficial effects. When non-human primates were fed a high-fat diet and given daily resveratrol for two-years (80 milligrams per day for the first year, then 480 milligrams per day for the second year) they exhibited increased SIRT1 expression, decreased inflammation due to diminished levels of NF-κB, decreased adipocyte (fat cell) size, and improved insulin sensitivity in visceral adipose tissue. In a similar study in non-human primates that were fed a diet high in refined sugar (sucrose) and fat for two years, the animals experienced a 40 percent increase in arterial stiffness and inflammation. However, when fed the same diet but also given 80 milligrams of resveratrol per day the first year, then 480 milligrams per day the second year, the primates were protected from arterial wall stiffness and inflammation.
Resveratrol treatment has been shown to reduce neuronal inflammation and improve cognitive performance by mitigating reactive oxygen species, inhibiting pro-inflammatory molecules such as cyclooxygenase-1, or COX1, and inhibiting beta-amyloid plaque formation and aggregation, a hallmark of Alzheimer's disease.
In a study of healthy adults aged 50-75 years, 200 milligrams of resveratrol taken per day for 26 weeks improved the participants' ability to complete memory tasks. Resveratrol has also shown promise in a phase 2 clinical trial for the treatment of Alzheimer's disease. Specifically, 56 patients diagnosed with Alzheimer's disease were treated with 500 milligrams of resveratrol once daily with a dose-escalation by 500 milligram increments every 13 weeks, ending with 1000 milligrams twice daily. The patients saw improvements in mental examination status scores, reduced cerebrospinal fluid amyloid-beta levels – a biomarker of Alzheimer's disease – and lowered cerebrospinal fluid matrix metalloproteinase 9, a mediator of neuroinflammation. Although this study demonstrated that resveratrol treatment may improve parameters associated with Alzheimer's disease, larger and longer studies are needed to determine whether resveratrol can promote cognitive and functional improvement.
Whether resveratrol may be beneficial for the treatment of cancer in humans is not currently known; however, numerous in vivo rodent studies have shown the potential of resveratrol for the treatment of pancreatic, prostate, colorectal, liver and breast cancer.  Before resveratrol can be considered a viable option for cancer therapy, more human studies are needed.
The use of resveratrol in cancer prevention might be more promising than cancer treatment, however. Two clinical studies in which healthy subjects received varying doses of resveratrol found that doses of 1 gram and 2.5 grams reduced IGF-1 (insulin-like growth factor 1), which is associated with tumor formation and metastasis. Furthermore, resveratrol treatment increased a variety of carcinogen-detoxifying enzymes, such as glutathione S-transferase and glucuronosyltransferase.  
Calorie restriction extends lifespan in multiple species, an effect that may be mediated in part by sirtuins, enzymes that play key roles in healthspan and longevity. Resveratrol, a potent activator of SIRT1, may mimic the effects of calorie restriction. In multiple species such as yeast, worms, and fish, resveratrol treatment has been shown to increase longevity . In healthy mammals, studies have yet to confirm that resveratrol supplementation extends lifespan. However, studies have shown that resveratrol supplementation can increase the lifespan of metabolically compromised animals. In particular, in a study in which mice were fed a high-fat diet supplemented with resveratrol, the mice had a 31 percent reduced risk of death and displayed a physiology similar to mice fed a standard chow diet without resveratrol.
Resveratrol's protective effects against age-related diseases are thought in large part to be mediated through sirtuins. Resveratrol has been shown to bind to sirtuins, altering their affinity for NAD+ and their protein substrates, thereby increasing sirtuins' activity. As such, resveratrol and other sirtuin-activating compounds present a promising therapeutic strategy to ameliorate age-related diseases and extend healthspan.
Autophagy is an adaptive response mechanism that is activated upon cellular stress to remove unnecessary or dysfunctional cellular components as well as mobilize stored energy reserves. Calorie restriction is a potent driver of autophagy through the activation of SIRT1.  While resveratrol directly activates sirtuins, it also induces autophagy independent of SIRT1 by inhibiting the activity of mTOR – mammalian target of rapamycin – which is a key regulator of autophagy. Resveratrol's autophagy-inducing capacity likely has implications for both aging and cancer.
Humans have evolved the ability to eat a wide range of plants. During both normal development and under conditions of stress, these plants produce a variety of compounds broadly referred to as phytochemicals. Examples include flavonols, anthocyanins, and resveratrol. In plants, these compounds may act as attractants for pollinators or serve as antioxidants or antifeedants – substances that adversely affect insects or animals, including humans, that feed on the plants.
In humans, phytochemicals can activate cellular stress response pathways which confer protective effects. This biological phenomenon, known as xenohormesis, switches on protective mechanisms that not only protect our cells from the phytochemicals themselves but also provide protection against the potential deterioration of our environment as well as the presence of damaging factors that we are exposed to on a daily basis such as air pollution or overexposure to UV radiation. Why animals, including humans, should respond with a stress response to compounds with otherwise low systemic toxicity has been the source of some speculation. One school of thought suggests that humans and animals use signals of plant stress, the unifying condition by which the production of many beneficial xenohormetic compounds are boosted, as signs that the environment may be demanding enhanced fitness.
The protective effects of resveratrol on humans may be mediated through a variety of cellular stress response pathways such as the activation of SIRT1, AMP-activated protein kinase (AMPK), and cyclic-AMP phosphodiesterase. SIRT1– a highly conserved enzyme that utilizes NAD+ – is linked to anti-inflammatory activity, metabolic adaptations, and neurological protection. AMPK is a fuel-sensing enzyme that can activate numerous pathways involved in catabolism – the breakdown of complex molecules such as fatty acids. AMPK can also inhibit mTOR, leading to the downregulation of cellular growth pathways.  Cyclic-AMP phosphodiesterase is an enzyme that breaks down cAMP – an intracellular signaling molecule – which increases cellular NAD+ levels. Resveratrol has been shown to inhibit cyclic-AMP phosphodiesterase, leading to an increase in NAD+ and SIRT1.  The activation of these cellular stress response pathways may in part mediate some of the beneficial effects as seen with calorie restriction.
Calorie restriction has widely been shown to increase lifespan across a wide range of organisms from bacteria to primates. With its ability to activate SIRT1 – the gene that likely mediates many of the positive benefits of calorie restriction – resveratrol is thought to be a calorie restriction mimetic.
A study in which mice were fed an obesogenic diet and treated with resveratrol found that the animals not only lived longer compared to mice that didn't receive resveratrol, but they experienced physiological changes typically seen with calorie restriction, such as reduced IGF-1 and increased AMPK activity.
In a study in which mice were fed a standard chow diet to test resveratrol's ability to mimic caloric restriction, resveratrol supplementation did not increase lifespan in the mice. However, the mice that received resveratrol exhibited changes in gene expression that mimicked calorie restriction and demonstrated improved overall health as reflected by reduced incidence of osteoporosis, cataracts, vascular dysfunction, and declines in motor coordination.
Although resveratrol has been shown to elicit beneficial effects on metabolic and neurological parameters, studies investigating the effects of resveratrol on exercise training are contradictory. One study involved 27 men between the ages of 60 and 72 years who participated in an 8-week training program with two days of cycling and one day of Crossfit. Each of the men took a 250 milligram resveratrol supplement daily. The resveratrol supplement blunted the positive effects of exercise training on blood pressure, blood cholesterol, and maximal oxygen uptake observed with exercise alone. However, a similar study involved 30 men and women between the ages of 65 and 80 years who participated in a 12-week resistance and aerobic training plan three days a week and took a 500 milligram supplement of resveratrol per day. At the end of the training program, the participants experienced an increase in mitochondrial density, muscle fibers, and maximal oxygen consumption compared to exercise training alone. Another study in which 22 year old men who engaged in four weeks of high-intensity interval training three days a week and supplemented with 150 milligrams of resveratrol per day, the lowest dose of the studies mentioned so far, did not promote increases in the men's aerobic or anaerobic capacity, exercise substrate utilization, or muscle fiber-specific adaptations compared to exercise alone.
The type of exercise, intensity, and the dose of resveratrol may contribute to these contradictory results. More studies are needed to determine how resveratrol supplementation affects exercise performance.
Resveratrol exists as a trans and cis isomer – a molecule with the same atoms but in a different arrangement. Trans-resveratrol is believed to be the most predominant and stable of the two forms while also eliciting the major health benefits. Trans-resveratrol should be protected from light as studies have shown that upon a few hours of solar or UV radiation, trans-resveratrol undergoes isomerization into the less active cis-resveratrol form. The majority of resveratrol supplements sold in the US contain the trans form of resveratrol, according to their labeling.
Resveratrol's bioavailability – the amount that is taken up in the gut and delivered to the remainder of the body's tissues – is only about 25 percent due to rapid metabolism and excretion.  Studies have shown that resveratrol metabolism varies in a circadian fashion, with higher bioavailability occurring in the morning. Resveratrol is water insoluble and studies have shown that resveratrol enclosed in a nanocapsule – a shell that encapsulates an inner core – can increase stability and bioavailability. Furthermore, a study in healthy human volunteers found that resveratrol exposure is increased when taken with a moderate fat breakfast (18 grams fat, 70 grams carbohydrate, and 12 grams protein) versus a very high fat breakfast (45 grams of fat, 60 grams of carbohydrates and 30 grams of protein) 
Other studies have shown that resveratrol supplementation in combination with piperine – a natural compound found in black pepper – may potentially increase bioavailability and efficacy by inhibiting enzymes involved in the metabolism of resveratrol. In mice given a single dose of resveratrol at 100 milligrams per kilogram of body weight along with piperine at 10 milligrams per kilogram of body weight resulted in a 1544 percent increase in serum concentration of resveratrol compared to mice only given resveratrol at 100 milligrams per kilogram of body weight.  However, a study in humans found that piperine does not improve bioavailability but may improve efficacy in regard to improved cerebral blood flow, which may benefit cognitive function. Specifically, 23 adults who took 250 milligrams of trans-resveratrol with 20 milligrams of piperine had an increase in cerebral blood flow. Further research is needed to determine whether piperine has the ability to increase bioavailability and efficacy of resveratrol.
A 5-ounce glass of red wine contains approximately 1.8 milligrams of resveratrol while therapeutic doses typically range from approximately 100 milligrams to 1 gram. Human trials of resveratrol supplementation have demonstrated that up to 5 grams of resveratrol per day do not cause toxicity or serious side effects.  A repeat dose study for 29 days in healthy volunteers showed that resveratrol supplementation of up to 5 grams was not toxic; however, doses above 2.5 grams were associated with mild to moderate gastrointestinal distress, such as nausea, flatulence (gas), abdominal discomfort, and diarrhea. Furthermore, in overweight adults who were 70 years of age or older, 2 grams of resveratrol taken daily for 90 days was well tolerated.
While resveratrol supplementation has been reported to have minimal side effects in multiple human trials, supplementation should be considered with caution. Hormetic effects in animal models have elicited adverse cardiovascular outcomes, particularly in rats given more than 25 milligrams per day. Long term toxicology studies in humans (longer than one year) have not been performed.
Studies have also shown that resveratrol supplementation may interfere with the way in which the body metabolizes other drugs. In particular, resveratrol inhibits cytochrome P450 enzymes, or CYPs, which are involved with the metabolism of many drugs such as statins, antiarrhythmic agents, and antihistamines. This inhibition could reduce the metabolic clearance of certain drugs leading to increased bioavailability and risk of toxicity.  
Resveratrol elicits a broad range of physiological responses such as activating anti-inflammatory and antioxidant response pathways and promoting the activation of SIRT1. These responses have translated to functional health improvements when used to treat people diagnosed with various metabolic diseases as well as Alzheimer's disease. Given resveratrol's ability to activate cellular protective mechanisms and act as a calorie restriction mimetic, it has the potential to be used as a preventive supplement. Although resveratrol has proven effective in treating metabolic disease and holds promise as a preventive therapy, more studies are needed to ensure safety for long term use and the proper dose.
Resveratrol benefits health in many ways - Dr. Patrick Sept 2019
- Hasan, Mohidul, and Hanhong Bae. An Overview of Stress-Induced Resveratrol Synthesis in Grapes: Perspectives for Resveratrol-Enriched Grape Products Molecules 22, no. 2 (February 2017): 294. https://doi.org/10.3390/molecules22020294.
- a b Bhullar, Khushwant S., and Basil P. Hubbard. Lifespan and healthspan extension by resveratrol Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease <i>Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease</i> 1852, no. 6 (June 2015): 1209–18. https://doi.org/10.1016/j.bbadis.2015.01.012.
- Mohar, Dilbahar S. The Sirtuin System: The Holy Grail of Resveratrol? Journal of Clinical & Experimental Cardiology 03, no. 11 (2012). https://doi.org/10.4172/2155-9880.1000216.
- Timmers, Silvie, Ellen Konings, Lena Bilet, Riekelt H. Houtkooper, Tineke van de Weijer, Gijs H. Goossens, Joris Hoeks, et al. Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans Cell Metabolism 14, no. 5 (November 2011): 612–22. https://doi.org/10.1016/j.cmet.2011.10.002.
- Crandall, Jill P., Valerie Oram, Georgeta Trandafirescu, Migdalia Reid, Preeti Kishore, Meredith Hawkins, Hillel W. Cohen, and Nir Barzilai. Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance The Journals of Gerontology: Series A 67, no. 12 (January 2012): 1307–12. https://doi.org/10.1093/gerona/glr235.
- Brasnyó, Pál, Gergő A. Molnár, Márton Mohás, Lajos Markó, Boglárka Laczy, Judit Cseh, Esztella Mikolás, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients British Journal of Nutrition 106, no. 3 (March 2011): 383–89. https://doi.org/10.1017/s0007114511000316.
- Movahed, Ali, Iraj Nabipour, Xavier Lieben Louis, Sijo Joseph Thandapilly, Liping Yu, Mohammadreza Kalantarhormozi, Seyed Javad Rekabpour, and Thomas Netticadan. Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–11. https://doi.org/10.1155/2013/851267.
- Abdollahi, Shima, Amin Salehi-Abargouei, Omid Toupchian, Mohammad Hasan Sheikhha, Hossein Fallahzadeh, Masoud Rahmanian, Mahtab Tabatabaie, and Hassan Mozaffari-Khosravi. The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial Phytotherapy Research , September 2019. https://doi.org/10.1002/ptr.6487.
- Chen, Shihui, Xiaolan Zhao, Li Ran, Jing Wan, Xiaofang Wang, Yu Qin, Furong Shu, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial Digestive and Liver Disease 47, no. 3 (March 2015): 226–32. https://doi.org/10.1016/j.dld.2014.11.015.
- Faghihzadeh, Forouzan, Peyman Adibi, Rahmatollah Rafiei, and Azita Hekmatdoost. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease Nutrition Research 34, no. 10 (October 2014): 837–43. https://doi.org/10.1016/j.nutres.2014.09.005.
- Tomé-Carneiro, Joao, Manuel Gonzálvez, Mar Larrosa, Francisco J. García-Almagro, Francisco Avilés-Plaza, Soledad Parra, María J. Yáñez-Gascón, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial Molecular Nutrition & Food Research 56, no. 5 (May 2012): 810–21. https://doi.org/10.1002/mnfr.201100673.
- Tomé-Carneiro, João, Manuel Gonzálvez, Mar Larrosa, María J. Yáñez-Gascón, Francisco J. García-Almagro, José A. Ruiz-Ros, María T. García-Conesa, Francisco A. Tomás-Barberán, and Juan Carlos Espín. One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease The American Journal of Cardiology 110, no. 3 (August 2012): 356–63. https://doi.org/10.1016/j.amjcard.2012.03.030.
- K., Magyar, Halmosi R., Palfi A., Feher G., Czopf L., Fulop A., Battyany I., Sumegi B., Toth K., and Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease Clinical Hemorheology and Microcirculation 50, no. 3 (2012): 179–87. https://doi.org/10.3233/CH-2011-1424.
- Ghanim, Husam, Chang Ling Sia, Sanaa Abuaysheh, Kelly Korzeniewski, Priyanka Patnaik, Anuritha Marumganti, Ajay Chaudhuri, and Paresh Dandona. An Antiinflammatory and Reactive Oxygen Species Suppressive Effects of an Extract ofPolygonum CuspidatumContaining Resveratrol The Journal of Clinical Endocrinology & Metabolism 95, no. 9 (September 2010): E1–E8. https://doi.org/10.1210/jc.2010-0482.
- Jimenez-Gomez, Yolanda, Julie A. Mattison, Kevin J. Pearson, Alejandro Martin-Montalvo, Hector H. Palacios, Alex M. Sossong, Theresa M. Ward, et al. Resveratrol Improves Adipose Insulin Signaling and Reduces the Inflammatory Response in Adipose Tissue of Rhesus Monkeys on High-Fat, High-Sugar Diet Cell Metabolism 18, no. 4 (October 2013): 533–45. https://doi.org/10.1016/j.cmet.2013.09.004.
- Mattison, Julie A., Mingyi Wang, Michel Bernier, Jing Zhang, Sung-Soo Park, Stuart Maudsley, Steven S. An, et al. Resveratrol Prevents High Fat/Sucrose Diet-Induced Central Arterial Wall Inflammation and Stiffening in Nonhuman Primates Cell Metabolism 20, no. 1 (July 2014): 183–90. https://doi.org/10.1016/j.cmet.2014.04.018.
- Rege, Shraddha D., Thangiah Geetha, Gerald D. Griffin, Tom L. Broderick, and Jeganathan Ramesh Babu. Neuroprotective effects of resveratrol in Alzheimer disease pathology Frontiers in Aging Neuroscience 6 (September 2014). https://doi.org/10.3389/fnagi.2014.00218.
- Witte, A. V., L. Kerti, D. S. Margulies, and A. Floel. Effects of Resveratrol on Memory Performance, Hippocampal Functional Connectivity, and Glucose Metabolism in Healthy Older Adults Journal of Neuroscience 34, no. 23 (June 2014): 7862–70. https://doi.org/10.1523/jneurosci.0385-14.2014.
- Moussa, Charbel, Michaeline Hebron, Xu Huang, Jaeil Ahn, Robert A. Rissman, Paul S. Aisen, and R. Scott Turner. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease Journal of Neuroinflammation 14, no. 1 (January 2017). https://doi.org/10.1186/s12974-016-0779-0.
- Carter, Lindsay G, John A D Orazio, and Kevin J Pearson. Resveratrol and cancer: focus on in vivo evidence Endocrine-Related Cancer 21, no. 3 (February 2014): R209–R225. https://doi.org/10.1530/erc-13-0171.
- a b Chow, H.-H. S., L. L. Garland, C.-H. Hsu, D. R. Vining, W. M. Chew, J. A. Miller, M. Perloff, J. A. Crowell, and D. S. Alberts. Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study Cancer Prevention Research 3, no. 9 (August 2010): 1168–75. https://doi.org/10.1158/1940-6207.capr-09-0155.
- a b Brown, V. A., K. R. Patel, M. Viskaduraki, J. A. Crowell, M. Perloff, T. D. Booth, G. Vasilinin, et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis Cancer Research 70, no. 22 (October 2010): 9003–11. https://doi.org/10.1158/0008-5472.can-10-2364.
- ^ a b Baur, Joseph A., Kevin J. Pearson, Nathan L. Price, Hamish A. Jamieson, Carles Lerin, Avash Kalra, Vinayakumar V. Prabhu, et al. Resveratrol improves health and survival of mice on a high-calorie diet Nature 444, no. 7117 (November 2006): 337–42. https://doi.org/10.1038/nature05354.
- Gertz, Melanie, Giang Thi Tuyet Nguyen, Frank Fischer, Benjamin Suenkel, Christine Schlicker, Benjamin Fränzel, Jana Tomaschewski, et al. A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol PLoS ONE Edited by Michael Massiah. 7, no. 11 (November 2012): e49761. https://doi.org/10.1371/journal.pone.0049761.
- Morselli, E, M C Maiuri, M Markaki, E Megalou, A Pasparaki, K Palikaras, A Criollo, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy Cell Death & Disease 1, no. 1 (January 2010): e10–e10. https://doi.org/10.1038/cddis.2009.8.
- Park, Dohyun, Heeyoon Jeong, Mi Nam Lee, Ara Koh, Ohman Kwon, Yong Ryoul Yang, Jungeun Noh, Pann-Ghill Suh, Hwangseo Park, and Sung Ho Ryu. Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition Scientific Reports 6, no. 1 (February 2016). https://doi.org/10.1038/srep21772.
- Howitz, Konrad T., and David A. Sinclair. Xenohormesis: Sensing the Chemical Cues of Other Species Cell 133, no. 3 (May 2008): 387–91. https://doi.org/10.1016/j.cell.2008.04.019.
- Malformed reference
- a b Lan, Fan, Karen Weikel, Jose Cacicedo, and Yasuo Ido. Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application Nutrients 9, no. 7 (July 2017): 751. https://doi.org/10.3390/nu9070751.
- Park, Sung-Jun, Faiyaz Ahmad, Andrew Philp, Keith Baar, Tishan Williams, Haibin Luo, Hengming Ke, et al. Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases Cell 148, no. 3 (February 2012): 421–33. https://doi.org/10.1016/j.cell.2012.01.017.
- Mattison, Julie A., Ricki J. Colman, T. Mark Beasley, David B. Allison, Joseph W. Kemnitz, George S. Roth, Donald K. Ingram, Richard Weindruch, Rafael de Cabo, and Rozalyn M. Anderson. Caloric restriction improves health and survival of rhesus monkeys Nature Communications 8, no. 1 (January 2017). https://doi.org/10.1038/ncomms14063.
- Chung, Jay H., Vincent Manganiello, and Jason R.B. Dyck. Resveratrol as a calorie restriction mimetic: therapeutic implications Trends in Cell Biology 22, no. 10 (October 2012): 546–54. https://doi.org/10.1016/j.tcb.2012.07.004.
- Pearson, Kevin J., Joseph A. Baur, Kaitlyn N. Lewis, Leonid Peshkin, Nathan L. Price, Nazar Labinskyy, William R. Swindell, et al. Resveratrol Delays Age-Related Deterioration and Mimics Transcriptional Aspects of Dietary Restriction without Extending Life Span Cell Metabolism 8, no. 2 (August 2008): 157–68. https://doi.org/10.1016/j.cmet.2008.06.011.
- Gliemann, Lasse, Jakob Friis Schmidt, Jesper Olesen, Rasmus Sjørup Biensø, Sebastian Louis Peronard, Simon Udsen Grandjean, Stefan Peter Mortensen, et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men The Journal of Physiology 591, no. 20 (August 2013): 5047–59. https://doi.org/10.1113/jphysiol.2013.258061.
- Alway, Stephen E, Jean L McCrory, Kalen Kearcher, Austen Vickers, Benjamin Frear, Diana L Gilleland, Daniel E Bonner, et al. Resveratrol Enhances Exercise-Induced Cellular and Functional Adaptations of Skeletal Muscle in Older Men and Women The Journals of Gerontology: Series A 72, no. 12 (May 2017): 1595–1606. https://doi.org/10.1093/gerona/glx089.
- Scribbans, Trisha D., Jasmin K. Ma, Brittany A. Edgett, Kira A. Vorobej, Andrew S. Mitchell, Jason G.E. Zelt, Craig A. Simpson, Joe Quadrilatero, and Brendon J. Gurd. Resveratrol supplementation does not augment performance adaptations or fibre-type specific responses to high-intensity interval training in humans Applied Physiology, Nutrition, and Metabolism 39, no. 11 (November 2014): 1305–13. https://doi.org/10.1139/apnm-2014-0070.
- Anisimova, Natalia YU, Mikhail V Kiselevsky, Andrey V Sosnov, Sergey V Sadovnikov, Ivan N Stankov, and Andrei A Gakh. Trans-, cis-, and dihydro-resveratrol: a comparative study Chemistry Central Journal 5, no. 1 (2011): 88. https://doi.org/10.1186/1752-153x-5-88.
- Figueiras, Teresa Sofia, Maria Teresa Neves-Petersen, and Steffen B. Petersen. Activation Energy of Light Induced Isomerization of Resveratrol Journal of Fluorescence 21, no. 5 (April 2011): 1897–1906. https://doi.org/10.1007/s10895-011-0886-3.
- Cottart, Charles-Henry, ValÃ rie Nivet-Antoine, Christelle Laguillier-Morizot, and Jean-Louis Beaudeux. Resveratrol bioavailability and toxicity in humans Molecular Nutrition & Food Research 54, no. 1 (January 2010): 7–16. https://doi.org/10.1002/mnfr.200900437.
- Soleas, George J., Mark Angelini, Linda Grass, Eleftherios P. Diamandis, and David M. Goldberg. Absorption of trans-resveratrol in rats Methods in Enzymology In , 145–54. Elsevier, 2001. https://doi.org/10.1016/s0076-6879(01)35239-4.
- Almeida, Luis, Manuel Vaz-da-Silva, Amílcar Falcão, Eva Soares, Raquel Costa, Ana I. Loureiro, Carlos Fernandes-Lopes, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers Molecular Nutrition & Food Research 53, no. S1 (February 2009): S7–S15. https://doi.org/10.1002/mnfr.200800177.
- Sessa, Mariarenata, Rong Tsao, Ronghua Liu, Giovanna Ferrari, and Francesco Donsì. Evaluation of the Stability and Antioxidant Activity of Nanoencapsulated Resveratrol during in Vitro Digestion Journal of Agricultural and Food Chemistry 59, no. 23 (December 2011): 12352–60. https://doi.org/10.1021/jf2031346.
- Porte, Charles la, Nha Voduc, Guijun Zhang, Isabelle Seguin, Danielle Tardiff, Neera Singhal, and D. William Cameron. Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 pace0.167emmg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects Clinical Pharmacokinetics 49, no. 7 (July 2010): 449–54. https://doi.org/10.2165/11531820-000000000-00000.
- Johnson, Jeremy J., Minakshi Nihal, Imtiaz A. Siddiqui, Cameron O. Scarlett, Howard H. Bailey, Hasan Mukhtar, and Nihal Ahmad. Enhancing the bioavailability of resveratrol by combining it with piperine Molecular Nutrition & Food Research 55, no. 8 (June 2011): 1169–76. https://doi.org/10.1002/mnfr.201100117.
- Wightman, Emma L., Jonathon L. Reay, Crystal F. Haskell, Gary Williamson, Tristan P. Dew, and David O. Kennedy. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation British Journal of Nutrition 112, no. 2 (May 2014): 203–13. https://doi.org/10.1017/s0007114514000737.
- Boocock, D. J., G. E.S. Faust, K. R. Patel, A. M. Schinas, V. A. Brown, M. P. Ducharme, T. D. Booth, et al. Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent Cancer Epidemiology Biomarkers & Prevention 16, no. 6 (June 2007): 1246–52. https://doi.org/10.1158/1055-9965.epi-07-0022.
- SERGIDES, CHRISTAKIS, MARINELA CHIRILĂ, LUIGI SILVESTRO, DAPHNE PITTA, and ANDREAS PITTAS. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers Experimental and Therapeutic Medicine 11, no. 1 (November 2015): 164–70. https://doi.org/10.3892/etm.2015.2895.
- Anton, Stephen D., Chelsea Embry, Michael Marsiske, Xiaomin Lu, Hani Doss, Christiaan Leeuwenburgh, and Todd M. Manini. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study Experimental Gerontology 57 (September 2014): 181–87. https://doi.org/10.1016/j.exger.2014.05.015.
- Juhasz, B., S. Mukherjee, and D. K. Das. Hormetic response of resveratrol against cardioprotection Exp Clin Cardiol 15, no. 4 (2010): e134–138.
- Detampel, Pascal, Mareike Beck, Stephan Krähenbühl, and Jörg Huwyler. Drug interaction potential of resveratrol Drug Metabolism Reviews 44, no. 3 (July 2012): 253–65. https://doi.org/10.3109/03602532.2012.700715.
- Hyrsova, Lucie, Alena Vanduchova, Jan Dusek, Tomas Smutny, Alejandro Carazo, Veronika Maresova, Frantisek Trejtnar, et al. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors Toxicology Letters 300 (January 2019): 81–91. https://doi.org/10.1016/j.toxlet.2018.10.028.
743 visitors, last modified 26 Sep, 2019,